诺华（NOVN.SW）股价与投研分析
Novartis · 欧洲市场 · 医药健康
关键指标
- 最新价
- CHF 134.12
- 日内涨跌
- -0.10%
- 市值
- CHF 2533.02 亿
- 市盈率 TTM
- 32.16
- 市净率
- 8.25
- 52 周最高
- CHF 135.22
- 52 周最低
- CHF 99.45
- 股息率
- 2.76%
- 成交量
- 股 503.82 万
- 上市市场
- 欧洲
公司概况
诺华（英文名 Novartis，股票代码 NOVN.SW）在欧洲市场上市， 属于医药健康行业，当前处于成熟阶段。核心标签：制药、创新药、高股息。
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
AI 三层投研框架
- 宏观周期层：利率、通胀、汇率与流动性如何影响欧洲市场的估值中枢。
- 行业格局层：用 PEST、波特五力与产业链位置判断医药健康行业的利润分配。
- 公司质地层：把 诺华 的增速、利润率、ROE 与现金流放进同行业横向对比。
需要完整报告？回到终端 可基于真实财报数据生成三层 AI 分析。